These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27371632)

  • 1. Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply.
    Herman SE; Wiestner A
    Clin Cancer Res; 2016 Jul; 22(13):3412. PubMed ID: 27371632
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.
    Zucchetto A; Tissino E; Hartmann TN; Chigaev A; Del Poeta G; Colombatti A; Gattei V
    Clin Cancer Res; 2016 Jul; 22(13):3410-1. PubMed ID: 27371631
    [No Abstract]   [Full Text] [Related]  

  • 3. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
    Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
    J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
    Herman SE; Mustafa RZ; Jones J; Wong DH; Farooqui M; Wiestner A
    Clin Cancer Res; 2015 Oct; 21(20):4642-51. PubMed ID: 26089373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
    Tissino E; Gaglio A; Nicolò A; Pozzo F; Bittolo T; Rossi FM; Bomben R; Nanni P; Cattarossi I; Zaina E; Zimbo AM; Ianna G; Capasso G; Forestieri G; Moia R; Datta M; Härzschel A; Olivieri J; D'Arena G; Laurenti L; Zaja F; Chiarenza A; Palumbo GA; Martino EA; Gentile M; Rossi D; Gaidano G; Del Poeta G; Laureana R; Del Principe MI; Maity PC; Jumaa H; Hartmann TN; Zucchetto A; Gattei V
    Leukemia; 2024 Oct; 38(10):2127-2140. PubMed ID: 39143370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation.
    Quinquenel A; Sicre de Fontbrune F; Durot E; Pannetier M; Michonneau D; Socié G; Delmer A; Peffault De Latour R
    Br J Haematol; 2017 Mar; 176(6):997-999. PubMed ID: 26991435
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ibrutinib - new tool in hematologist hand, new challenges for internist].
    Majcherek M; Dworacka M; Dworacki G
    Wiad Lek; 2017; 70(1):92-95. PubMed ID: 28343201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    van der Straten L; Levin MD; Visser O; Blijlevens NMA; Cornelissen JJ; Doorduijn JK; Kater AP; Dinmohamed AG
    Br J Haematol; 2020 Mar; 188(6):e109-e112. PubMed ID: 31991479
    [No Abstract]   [Full Text] [Related]  

  • 10. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
    Lenz G
    J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Rozovski U; Harris DM; Li P; Liu Z; Jain P; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
    Leuk Lymphoma; 2018 Nov; 59(11):2686-2691. PubMed ID: 29465264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BTK in CLL: Beyond Ibrutinib.
    Bond DA; Woyach JA
    Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
    Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
    Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
    Tam CS; Kimber T; Seymour JF
    Br J Haematol; 2017 Mar; 176(5):829-831. PubMed ID: 26915463
    [No Abstract]   [Full Text] [Related]  

  • 17. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Ayed AO; Parikh SA
    Leuk Lymphoma; 2018 Oct; 59(10):2287-2296. PubMed ID: 29115892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of ibrutinib in chronic lymphocytic leukemia.
    Damon LE
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibrutinib in the real world patient: many lights and some shades.
    Ghia P; Cuneo A
    Haematologica; 2016 Dec; 101(12):1448-1450. PubMed ID: 27903711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.